Current Opinion in Oncology

Papers
(The TQCC of Current Opinion in Oncology is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)
ArticleCitations
Epidemiology of head and neck cancers: an update165
Lung cancer in China: current and prospect149
Molecular alterations in meningioma: prognostic and therapeutic perspectives52
Advances in immunotherapy for cervical cancer47
Models of supportive care in oncology36
Viral strategies for circumventing p53: the case of severe acute respiratory syndrome coronavirus32
Malignant pleural mesothelioma: recent developments28
BRAF mutations in thyroid cancer28
Antibody–drug conjugates in breast cancer: the chemotherapy of the future?27
Recent progress in treating advanced prostate cancer24
CD19-directed CAR T-cell therapy in B-cell NHL23
Current emerging MRI tools for radionecrosis and pseudoprogression diagnosis23
Current concepts in the treatment of giant cell tumour of bone22
Targeting HER2 heterogeneity in early-stage breast cancer20
Sinonasal cancers treatments: state of the art19
Resistance mechanisms to osimertinib and emerging therapeutic strategies in nonsmall cell lung cancer18
Multimodality treatment for localized gastric cancer: state of the art and new insights18
Adjuvant chemotherapy in pancreatic cancer: state of the art and future perspectives17
The roaring 2020s: a new decade of systemic therapy for renal cell carcinoma17
T-cell-engaging antibodies for the treatment of solid tumors: challenges and opportunities17
Targeting SUMOylation in cancer17
Geriatric assessments and frailty scores in multiple myeloma patients: a needed tool for individualized treatment?16
Immunotherapy and breast cancer: an overview15
New drugs in gastrointestinal stromal tumors15
MEK inhibitors in RASopathies15
Updated concepts in treatment of giant cell tumor of bone15
Targeted radionuclide therapy: an emerging field in solid tumours14
Next-generation sequencing for the management of sarcomas with no known driver mutations14
Clinical data, limitations and perspectives on chimeric antigen receptor T-cell therapy in multiple myeloma14
New targets and technologies for CAR-T cells14
Mechanisms of invasion in glioblastoma14
The role of the tumor matrix environment in progression of head and neck cancer14
Cabozantinib as an emerging treatment for sarcoma14
Progress in the management of endometrial cancer (subtypes, immunotherapy, alterations in PIK3CA pathway): data and perspectives13
Challenges and opportunities in the management of metastatic renal cell carcinoma: combination therapy and the role of cytoreductive surgery13
Opportunities and challenges associated with the evaluation of chimeric antigen receptor T cells in real-life13
The role of myeloid-derived suppressor cells in hematologic malignancies13
Triplet combination of BRAF, MEK and PD-1/PD-L1 blockade in melanoma: the more the better?13
Adjuvant therapy of operable nonsmall cell lung cancer: an update13
The emerging data on choice of optimal therapy for locally advanced nasopharyngeal carcinoma13
Adrenocortical carcinoma: current treatment options13
Retroperitoneal sarcoma: the Transatlantic Australasian Retroperitoneal Sarcoma Working Group Program13
The evolving treatment paradigm of advanced hepatocellular carcinoma: putting all the pieces back together12
Adjuvant chemotherapy in rectal cancer: state of the art and future perspectives12
EGFR-mutant NSCLC: emerging novel drugs11
Lifestyle and quality of life in patients with early-stage breast cancer receiving adjuvant endocrine therapy11
Therapeutic targeting of the DNA damage response in prostate cancer11
Management of epilepsy in brain tumor patients11
Image-guided surgery in oral cancer: toward improved margin control11
Interventions addressing fear of cancer recurrence: challenges and future perspectives10
An update on adult forms of hereditary pheochromocytomas and paragangliomas10
Integrating new oral selective oestrogen receptor degraders in the breast cancer treatment10
Treatment updates on tenosynovial giant cell tumor10
Mitogen-activating protein kinase pathway alterations in Langerhans cell histiocytosis10
Role of Poly (ADP-Ribose) Polymerase inhibitors beyond BReast CAncer Gene-mutated ovarian tumours: definition of homologous recombination deficiency?10
Preoperative immunotherapy for head and neck cancers: state of art10
Harnessing dendritic cells for innovative therapeutic cancer vaccines10
New perspectives on targeting RAF, MEK and ERK in melanoma9
Novel therapeutic options for alveolar soft part sarcoma: antiangiogenic therapy, immunotherapy and beyond9
Bromodomain and extraterminal domain protein bromodomain inhibitor based cancer therapeutics9
Systemic treatment of metastatic squamous cell carcinoma of the head and neck: proposal for management changes9
Indications of next-generation sequencing in non-Hodgkin's lymphoma9
Adjuvant chemotherapy in colon cancer: state of the art and future perspectives9
Tropomyosin receptor kinase inhibitors in the management of sarcomas9
131I-metaiodobenzylguanidine and peptide receptor radionuclide therapy in pheochromocytoma and paraganglioma9
Overcoming key challenges in cancer immunotherapy with engineered T cells9
Immune escape mechanisms in head and neck squamous cell carcinoma and implication for new immunotherapy approach8
Recent advances in primary resistance mechanisms against immune checkpoint inhibitors8
Combining immunotherapy and radiotherapy in head and neck squamous cell cancers: which perspectives?8
Beyond ibrutinib: novel BTK inhibitors for the treatment of chronic lymphocytic leukemia8
New molecular entities of soft tissue and bone tumors8
Perspectives in pathomics in head and neck cancer8
EBV-associated NK and T-cell lymphoid neoplasms8
Targeting the methionine−methionine adenosyl transferase 2A−S-adenosyl methionine axis for cancer therapy8
Current status of phosphoinotiside-3 kinase inhibitors in blood cancers8
Is less more in the surgical treatment of early-stage cervical cancer?8
Novel immunotherapeutic drugs for the treatment of lung cancer8
Primary vitreoretinal lymphoma: short review of the literature, results of a European survey and French guidelines of the LOC network for diagnosis, treatment and follow-up8
Anaplastic thyroid carcinoma: advances in molecular profiling and targeted therapy8
Immunomodulation for hepatocellular carcinoma therapy: current challenges8
Epigenetic focus on angioimmunoblastic T-cell lymphoma: pathogenesis and treatment8
Lung cancer screening: a critical appraisal7
Targeting microRNA in hematologic malignancies7
Adjuvant chemotherapy in biliary tract cancer: state of the art and future perspectives7
COVID-19 and supportive cancer care: key issues and opportunities7
Targeting the DNA damage response beyond poly(ADP-ribose) polymerase inhibitors: novel agents and rational combinations7
Desmoid tumors: who, when and how to treat?7
Medical treatment of advanced malignant perivascular epithelioid cell tumors7
Role of metabolic imaging in diagnosis of primary, metastatic, and recurrent prostate cancer7
Prognostic factors in primary central nervous system lymphoma7
Biomarkers and immunotherapy: where are we?6
Cost-effectiveness of newer regimens for the prophylaxis of chemotherapy-induced nausea and vomiting: review of the literature and real-world data6
Supportive care for new cancer therapies6
Mutational burden and immune recognition of gliomas6
The road to chemotherapy-free treatment in chronic lymphocytic leukaemia6
Desmoid-type fibromatosis: toward a holistic management6
Can we cure oligometastatic disease? A practical point of view6
Current treatments of medulloblastoma6
Bacterial infection-driven lymphomagenesis6
Tyrosine kinase inhibitors as induction therapy in nonsmall-cell lung cancer6
Antibodies targeting Prostate-Specific Membrane Antigen positive prostate cancer: from diagnostic imaging to theranostics6
HIPEC in advanced epithelial ovarian cancer: why is there controversy?6
0.025497198104858